Poliovirus Therapy for Recurrent Glioblastoma Has 3-Year Survival Rate of 21%
Phase 1 study of Duke therapy shows long-term survival benefit for a lethal cancer
A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, with a three-year survival rate of 21 percent in a phase 1 clinical trial.
Comparatively, just 4 percent of patients at Duke with the same type of recurring brain tumors were alive at three years when undergoing the previously available standard treatment.
Click here to read more.
Calendar/Courses
The New England Master Class - Anterior Skull Base Surgery
May 20-21, 2019; Boston
6th Annual Meeting on Neurosurgery and Neurologica
May 22-23, 2019; London
INS 14th World Congress
May 25-30, 2019; Sydney
12th Annual Cervical Spine Research Society Hands-on Cadaver Course
May 30-June 1, 2019; St. Louis
Brain Tumor Biotech Summit
June 7, 2019; New York
